(Q35009893)

5 August 2017

1 reference

title

Raltitrexed: optimism and reality (English)

1 reference

5 August 2017

Kenneth S Wilson

1

1 reference

5 August 2017

Suzanne C Malfair Taylor

series ordinal

2

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

Expert Opinion on Drug Metabolism & Toxicology

5 August 2017

published in

1 reference

5 August 2017

volume

5

1 reference

5 August 2017

issue

11

1 reference

5 August 2017

page(s)

1447-1454

1 reference

Fluorinated pyrimidines, a new class of tumour-inhibitory compounds

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425250903307455

Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903307455

Tomudex (ZD1694): from concept to care, a programme in rational drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903307455

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903307455

Why hasn't the National Institute been 'NICE' to patients with colorectal cancer? National Institute of Clinical Excellence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903307455

Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903307455

Clinical and preclinical pharmacokinetics of raltitrexed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903307455

Systematic overview of warfarin and its drug and food interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903307455

Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903307455

Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903307455

Lessons learned from raltitrexed--quality assurance, patient education and intensive supportive drugs to optimise tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903307455

Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903307455

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903307455

Adjuvant therapy with raltitrexed in patients with colorectal cancer intolerant of 5-fluorouracil: British Columbia Cancer Agency experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903307455

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903307455

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903307455

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903307455

Raltitrexed: current clinical status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425250903307455

10.1517/17425250903307455

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference